Benitec Biopharma (BNTC) EBIT Margin (2019 - 2023)

Benitec Biopharma (BNTC) posted EBIT Margin of 65000.0% for Q2 2023, down 708.57% sequentially from 8038.89% in Q1 2023.

Benitec Biopharma (BNTC) EBIT Margin (2019 - 2023) Analysis & Trends

Benitec Biopharma has reported EBIT Margin for 5 years, with the latest figure at 65000.0% in Q2 2023.

Quarterly EBIT Margin changed N/A year-over-year to 65000.0% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 307028.57% (down 27869181.0% YoY) and the FY2023 annual result came in at 25441.33%, down 98380.0% from the prior year.
EBIT Margin fell to 65000.0% in Q2 2023 per BNTC's latest filing, from 8038.89% in the prior quarter.
Over five years, EBIT Margin peaked at 8248.57% in Q2 2020 and troughed at 379300.0% in Q1 2021.
A 5-year average of 80620.4% and a median of 8038.89% in 2023 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2021 and 2022: EBIT Margin slumped 37176071 bps in 2021, then soared 37209167 bps in 2022.
Over 5 years, EBIT Margin stood at 2741.56% in 2019, then sank by 11787 bps to 325900.0% in 2020, then surged by 94 bps to 19340.0% in 2021, then sank by 107 bps to 40071.43% in 2022, then tumbled by 62 bps to 65000.0% in 2023.
According to Business Quant data, EBIT Margin over the past three periods registered 65000.0%, 8038.89%, and 40071.43% for Q2 2023, Q1 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-105.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Benitec Biopharma	577.39 Mn	388.49 Mn	-	-

Download Data